In the first detailed in vivo and in vitro study in this regard by Huang et al., the treatment of HNSCC with the anti-EGFR antibody, C225 reduced cell-to-cell interaction between human umbilical vascular endothelial cells, resulting in the disruption of tube formation. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.